All In Biotech

Drug Trial Radar · NCT07233070

HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of HRS-7450 Injection in Patients With Acute Ischemic Stroke.

Last checked: Nov 20, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 210 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

210

Actual

Start

Oct 31, 2025

Primary completion

Sep 17, 2026

Study completion Sep 17, 2026

Sponsor

Sponsor type
Industry
First posted
Nov 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study plans to enroll a total of 208 patients with Acute Ischemic Stroke (AIS) who present within 4.5 to 24 hours of symptom onset and meet the specified imaging criteria.

Conditions

  • Acute Ischemic Stroke

Interventions

  • HRS-7450 InjectionDrug

    HRS-7450 Injection; low dose

  • HRS-7450 InjectionDrug

    HRS-7450 Injection; Intermediate dose

  • HRS-7450 InjectionDrug

    HRS-7450 Injection; high dose

  • HRS-7450 Injection PlaceboDrug

    HRS-7450 Injection Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. mRS score of 0-1 at 90 daysTime frame: within 90 days after the start of administration

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Sun Yat-sen University

    Guangzhou, Guangdong, China

  • Linyi People's Hospital

    Linyi, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.